A Comprehensive Review on Novel Liposomal Methodologies, Commercial Formulations, Clinical Trials and Patents

Andra, Veera Venkata Satya Naga Lakshmi; Pammi, S. V. N.; Bhatraju, Lakshmi Venkata Krishna Priya; Ruddaraju, Lakshmi Kalyani

doi:10.1007/s12668-022-00941-x

Cited by 89 publications

(39 citation statements)

References 95 publications

(89 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Longer circulating half-life, improved organ distribution, higher intracellular drug amounts, improved therapeutic effects, increased maximum tolerated doses, and reduced toxicities are frequently reported. (Deodhar and Dash, 2018;Salehi et al, 2020;Ren et al, 2021;Andra et al, 2022).…”

Section: Forces Driving Randd In Liposomal Drug Developmentmentioning

confidence: 99%

Regulatory Considerations Specific to Liposome Drug Development as Complex Drug Products

Wang¹,

Grainger

2022

Front. Drug. Deliv.

View full text Add to dashboard Cite

Nearly a half-century after original liposome discovery as a prospective lipid pharmaceutical carrier, the global liposomal drug delivery market has increased dramatically, with an annual market growth rate of 13.2%, valued at ∼$6,993 million by 2027. As an intrinsically complex delivery system, liposomal formulations face much greater characterization and regulatory review challenges than traditional small molecule drugs and biologics. Due to rapid liposomal drug development, both European Medicines Agency (EMA) and US Food and Drug Administration (FDA) now provide regulatory guidance for new liposomal drug application reviews. The expanding global liposome drug market and associated driving forces for increased research and development (R&D) in novel liposomal products are key factors propelling liposomal drug interests. We review and compare EU and US regulations on liposomal drug submissions, and provide insights into regulatory strategies throughout the entire liposomal drug development process. This addresses current gaps noted between liposome-based drug development in research labs and current regulatory guidance for liposomal drug approvals in order to facilitate more efficient, less costly, and less risky complex drug development.

show abstract

Section: Forces Driving Randd In Liposomal Drug Developmentmentioning

confidence: 99%

Regulatory Considerations Specific to Liposome Drug Development as Complex Drug Products

Wang¹,

Grainger

2022

Front. Drug. Deliv.

View full text Add to dashboard Cite

show abstract

“…Finally, the uniformity of liposomes is formed following extrusion through polycarbonate membranes. The main disadvantages are low encapsulation, difficulties in scaling up, and heterogeneous size distribution A [ 55 ]. Reema Narayan et al.…”

Section: Synthesis Of Liposomesmentioning

confidence: 99%

Liposomes: An emerging carrier for targeting Alzheimer's and Parkinson's diseases

Pandian

Vijayakumar

Murugesan³

et al. 2022

Heliyon

View full text Add to dashboard Cite

“…In liposomal targeted therapy, ultrasound can be used for two different applications: (1) liposome preparation and (2) drug release stimulation. As for liposome synthesis, sonication is widely used to downsize multilamellar vesicles (MLVs) to small unilamellar vesicles (SUVs) [ 62 , 63 , 64 ]. Optimization of liposome size is essential as large-sized liposomes are more rapidly cleared by RES and thus have a shorter blood lifespan compared to small-sized liposomes [ 65 ].…”

Section: Ultrasound As An External Triggering Modalitymentioning

confidence: 99%

Ultrasound Triggering of Liposomal Nanodrugs for Cancer Therapy: A Review

2022

View full text Add to dashboard Cite

Efficient conventional chemotherapy is limited by its nonspecific nature, which causes severe systemic toxicity that can lead to patient discomfort and low therapeutic efficacy. The emergence of smart drug delivery systems (SDDSs) utilizing nanoparticles as drug nanocarriers has shown great potential in enhancing the targetability of anticancer agents and limiting their side effects. Liposomes are among the most investigated nanoplatforms due to their promising capabilities of encapsulating hydrophilic, lipophilic, and amphiphilic drugs, biocompatibility, physicochemical and biophysical properties. Liposomal nanodrug systems have demonstrated the ability to alter drugs’ biodistribution by sufficiently delivering the entrapped chemotherapeutics at the targeted diseased sites, sparing normal cells from undesired cytotoxic effects. Combining liposomal treatments with ultrasound, as an external drug release triggering modality, has been proven effective in spatially and temporally controlling and stimulating drug release. Therefore, this paper reviews recent literature pertaining to the therapeutic synergy of triggering nanodrugs from liposomes using ultrasound. It also highlights the effects of multiple physical and chemical factors on liposomes’ sonosensetivity, several ultrasound-induced drug release mechanisms, and the efficacy of ultrasound-responsive liposomal systems in cancer therapy. Overall, liposomal nanodrug systems triggered by ultrasound are promising cancer therapy platforms that can potentially alleviate the detriments of conventional cancer treatments.

show abstract

A Comprehensive Review on Novel Liposomal Methodologies, Commercial Formulations, Clinical Trials and Patents

Cited by 89 publications

References 95 publications

Regulatory Considerations Specific to Liposome Drug Development as Complex Drug Products

Regulatory Considerations Specific to Liposome Drug Development as Complex Drug Products

Liposomes: An emerging carrier for targeting Alzheimer's and Parkinson's diseases

Ultrasound Triggering of Liposomal Nanodrugs for Cancer Therapy: A Review

Contact Info

Product

Resources

About